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Abstract The spectrum of HIV-associated neurocognitive
disorder (HAND) has been dramatically altered in the setting
of widely available effective antiretroviral therapy (ART).
Once culminating in dementia in many individuals infected
with HIV, HAND now typically manifests as more subtle,
though still morbid, forms of cognitive impairment in persons
surviving long-term with treated HIV infection. Despite the
substantial improvement in severity of this disorder, the fact
that neurologic injury persists despite ART remains a chal-
lenge to the community of patients, providers and investiga-
tors aiming to optimize quality of life for those living with
HIV. Cognitive dysfunction in treated HIV may reflect early
irreversible CNS injury accrued before ART is typically initi-
ated, ongoing low-level CNS infection and progressive injury
in the setting of ART, or comborbidities including effects of
treatment which may confound the beneficial reduction in
viral replication and immune activation effected by ART.
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Introduction
More than 25 years after the initial recognition that HIV can
directly damage the central nervous system (CNS) and lead to
dementia [1], HIV-associated neurocognitive disorder (HAND)
now encompasses a transformed spectrum of conditions due to
the relative immune recovery or immune preservation facilitated
by dramatic advances in antiretroviral therapy (ART). Though
in the early days HAND presented as a severe motor and
cognitive disorder in patients with advanced immunosuppres-
sion and AIDS, it now typically manifests as milder distur-
bances of psychomotor speed, processing speed, executive
function, or memory [2••, 3]. Despite this much more subtle
degree of impairment, HAND in the current era may affect daily
function, antiretroviral adherence, and quality of life [4–6].
Severe forms of dementia, myelopathy, and neuropathy do still
present in resource-limited settings, in patients with challenges
to adherence, and in thosewho present late to HIV care. The fact
that milder forms of HAND persist in resource rich settings
despite the widespread use of effective ART [2••, 7, 8] remains a
puzzle and challenge to providers and HIV-infected individuals.
This review will focus on the current state of knowledge of the
natural history of HIV in the CNS including establishment of
CNS reservoirs for infection and injury, as well as address new
issues and CNS disease entities emerging in the setting of
antiretroviral therapy.
Acute and Early HIV in the CNS and Effects of Early
Treatment
Crucial processes in systemic HIV pathogenesis are initiated
in acute and early HIV infection, including establishment of
tissue HIV reservoirs, massive CD4 memory phenotype T cell
loss, and establishment of viral and immune activation set
points [9, 10]. The recognition that this period is crucial to
disease pathogenesis and the possibility that early intervention
with ART might preserve immune status and reduce seeding
of viral reservoirs [11] has likewise raised the question of
whether the nervous system is importantly affected by HIV
during early HIVor may be protected by early treatment.
HIV Neuroinvasion and Establishment of CNS Infection
Until recently, an understanding of the processes occurring
in the CNS in the earliest stages of HIV infection have been
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informed almost entirely by animal models which allow for
interrogation of the CNS after a known timing of initial
lentiviral infection. In an accelerated rhesus macaque model
of neuro-AIDS [12], CNS SIV invasion occurs in the first
two weeks of infection, with detectable SIV in both the
cerebrospinal fluid (CSF) and brain [13, 14]. Acute SIV is
associated with brain infiltration of inflammatory T-cells,
cytokine production and microglial activation [15–17], and
the degree of elevation of CSF markers of immune activation
(rather than CSF viral load) during acute and early infection
is predictive of subsequent CNS disease [18]. SIV replication
has been demonstrated in macrophages and microglia during
the very early stages of infection in this accelerated model
[19]. While RNA production is halted by initiation of treat-
ment, levels of SIV DNA appear to be unaffected by com-
bination ART, and measures of CNS inflammation may
remain elevated in the setting of treatment [20•]. These
studies suggest that acute SIV sets the stage for immune
activation and infection in the CNS, and that a reservoir of
infection may be established early during the course of
disease which persists despite therapy. However, the gener-
alizability of findings in an accelerated model with immune-
depleted animals inoculated with neurovirulent HIV strains
to the natural history of HIV in humans is uncertain.
In humans, acute HIV is associated with a systemic acute
retroviral syndrome in up to 70 % of individuals [21]. In a
subset of these, specific neurological signs and symptoms
develop, including meningitis, encephalitis, mononeuropa-
thies, brachial neuritis, meningoradiculitis, myelopathy and
cauda equina syndrome [22–31]. The common features of
these diverse disorders include emergence a few weeks after
the onset of a systemic retroviral syndrome and a typically
self-limited course, suggesting an autoimmune rather than
HIV-specific etiology. However, in the majority of persons,
HIV entry into the nervous system is neurologically asymp-
tomatic, or associated only with headache [21, 32, 33]. Initial
HIV neuroinvasion in humans has been known to occur
within the first months of HIV, based on findings of HIV
nucleic acid and proviral DNA within the cerebral cortex by
day 15 after an iatrogenic acute HIV infection [34], and
surveys of tissue compartments during the first months of
HIV exposure [35, 36]. A recent systematic study of 96
subjects during primary HIV (within 12 months of infection)
detected HIV in the CSF in a majority of individuals at a
median 77 days post infection, indicating viral entry into the
CNS compartment [37]. Of these subjects 15 % had CSF HIV
RNA below the level of detection of standard assays in the
setting of high plasma HIV RNA. In a separate study of
subjects with acute HIV (median 14.5 days post infection) in
Bangkok, Thailand, HIV RNA was measurable in CSF by a
standard PCR assay in 15/18 subjects assessed within the first
30 days of estimated infection [38•], with higher median CSF
HIV levels than in the primary infection cohort. This study
also provided the earliest evidence of CNS entry of HIV in
humans, measuring a viral load of 2.88 log10copies/ml in the
CSF in one subject by 8 days post estimated infection. Taken
together, data from these two cohorts suggest that HIV enters
the CNS in the initial weeks after HIV exposure, but immune
responses may control HIV RNA in the CSF in the early
months of infection, in some individuals to undetectable levels
(see Fig. 1). In chronic infection such local control is lost, with
detectable CSF HIV a ubiquitous feature.
In chronic, established infection, HIV DNA has been recov-
ered from homogenized brain tissue and specific cell types in
the CNS including macrophages, microglia, and astrocytes,
supporting the concept of anatomic and cellular reservoirs for
HIVwithin the CNS [39–42]. Recent analysis of paired plasma
and CSF samples from subjects with early HIV infection shows
that in some cases early CSF HIV quasispecies are compart-
mentalized with respect to the blood, possibly suggesting an
autonomous source of viral production in the CNS compart-
ment within the first year after initial HIV transmission [43].
Overall, evidence of early seeding of the CNS compartment
and examples of CNS compartmentalization of HIV species
during early infection suggests that a CNS ‘reservoir’ for local
HIV infection and production may need to be considered in
treatment and HIVeradication strategies throughout the course
of HIV infection.
Pathogenesis of Acute and Early HIV in the CNS
Initial viral entry is fundamentally associated with evidence
of CNS inflammation and immune activation, based both on
CSF measures of cytokines and biomarkers of cellular acti-
vation and on neuroimaging measures which detect bio-
chemical and cellular metabolites indicative of inflammation
and gliosis within the brain parenchyma [37, 38•, 44, 45].
CNS immune activation is the putative substrate of CNS
injury in HIV; neurons are not productively infected and
neuronal dysfunction is thought to be mediated by indirect
effects of macrophage and microglial activation and astro-
cyte dysfunction and possibly neurotoxic effects of viral
proteins [46, 47]. Thus, an essential clinical question is
whether presence of inflammation and HIV virions within
the CNS might damage the brain during the early stages of
infection, prior to typical diagnosis of HIV and initiation of
treatment. Besides revealing prominent neuroinflammatory
patterns in acute infection [38•, 45], neuroimaging measures
have revealed mild reductions in brain imaging markers of
neuronal integrity [48, 49] as well as evidence of brain
atrophy [50], disruptions in brain connectivity networks
[51], and reduced cerebral blood flow [52] in subjects
assessed within the first year of infection. CSF markers
may also be sensitive to subtle ‘subclinical’ CNS injury
which may have longer-term consequences. Recently, mild
elevations in CSF levels of the light subunit of neurofilament
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protein (NFL), indicative of active neuronal breakdown, were
identified in almost half of a group of 92 largely
neuroasymptomatic subjects at a median 3.1 months post
infection [53•], consistent with a prior smaller report including
some of the same subjects [54]. The strongest independent
predictors of CSF NFL level in this group were CSF
neopterin, a pteridine product produced by activated macro-
phages and microglia within the CNS, and CSF to plasma
albumin ratio which rises with dysfunction of the blood brain
barrier. CSF NFL levels also inversely correlated with brain
neuroimaging markers of neuronal integrity. The clinical sig-
nificance of the low level elevations in NFL seen in this group
is uncertain, but these findings indicate that active injury to
neurons does occur during even the early stages of HIV
infection, and that this injury is closely associated with
neuroinflammation and disruption of the blood brain barrier.
Neurocognitive Function in Acute and Early Infection
Clinical studies have suggested that neuropsychological per-
formance and indices of mood may be worse in subjects with
early HIV infection compared with those in HIV-uninfected
control subjects or published norms [55, 56]. Deficits are
similar in pattern to those seen in subjects with chronic,
treated HIV infection, including impairments in learning
and processing speed. However, comorbidities may contrib-
ute to these differences, since subjects with recent HIV-
infection by nature have higher rates of substance use, other
sexually transmitted diseases, and mental health disorders
than the general population. A recent examination of the
contribution of co-morbid factors to these measures revealed
that impaired neuropsychological performance correlated
with methamphetamine use in subjects with recent HIV
infection [57]. This finding indicates that HAND reported
during this early stage may not be due to HIV alone, raising
the question of whether simply controlling HIV replication
during early infection will have a neurological benefit.
Impact of Early Antiretroviral Treatment
Though results of recent studies of early infection challenge the
prevailing assumption that HIV-associated neurologic injury
occurs only in the late stages of infection, these data do not yet
prove that CNS infection, inflammation, and neural injury
during this early period are predictive of neurological out-
comes. Furthermore, it is unclear whether the early initiation
of antiretroviral therapy may protect the CNS. Immediate
initiation of ART in subjects identified in the very early acute
Thai cohort has been associated with improvement in inflam-
matory brain metabolites measured through proton magnetic
resonance spectroscopy (MRS), with median levels reduced to
those measured in HIV-uninfected control subjects [45].
However, in this study, individual subjects with the highest
baseline inflammatory metabolite measures had persistently
elevated levels of brain inflammation after treatment,
suggesting a failure of complete cessation of CNS inflamma-
tion with therapy in some subjects despite extremely early
initiation of ART. This finding is consistent with the more
general observation that CSF immune activation, brain inflam-
mation detected by MRS, and microglial activation in brain
tissue persist in patients on long-term suppressive ART started
during the chronic stage of infection [40, 58–61]. Persistent
CNS immune activation associates with levels of detectable
CSF HIV RNA in suppressive ART and brain HIV DNA in
presymptomatic subjects [41, 59, 62], indicating that CNS
inflammation may be a surrogate for magnitude or activity of
Fig. 1 Paired HIV RNA levels in the blood (red) and cerebrospinal
fluid (blue) compartments with respect to estimated days post HIV
infection at initial sampling in antiretroviral naïve subjects with acute
and primary HIV infection. Circles denote values measured in acute
HIV subjects in Thailand with predominantly subtype CRF01_AE virus
(adapted from [37], with permission); triangles denote values obtained
in subjects from the USA, Sweden, Italy, and Australia with predomi-
nantly subtype B virus (updated from [38•], with permission). Note the
approximately 15 percent of CSF samples with HIV RNA concentra-
tions at or below the standard level of detection (50 copies/ml), often in
the presence of high plasma HIV RNA, within the first 6 months after
infection
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brain HIV reservoirs. Further studies are needed to indicate
whether very early initiation of ART may effectively abrogate
HIV infection and inflammation within the CNS. Studies of
neuropsychological performance in these subjects prior to and
longitudinally after immediate initiation of ART are ongoing.
The overall concept that ART initiation prior to advanced
immunosuppression may be beneficial to the CNS has been
supported by observations that CD4 nadir is an important
predictor of neurocognitive performance in treated subjects
with chronic infection [2••, 63, 64]. A recent report examining
HIV-infected and uninfected persons affiliated with the US
military [65] has more directly assessed whether a short dura-
tion of infection prior to treatment initiation may be associated
with preservation of neurologic and cognitive function. The
200 HIV-infected subjects enrolled in this study had prior
routine testing, resulting in known seroconversion within less
than a 1.5 year window. These subjects also had low preva-
lence of substance use and free access to HIV care from early
in the disease course such that the majority had initiated ART
within approximately 3 years of initial HIV infection. Rates of
neurocognitive impairment based on neuropsychological test-
ing were similar between these early-treated HIV infected
subjects and 100 HIV-uninfected matched subjects, suggesting
that a shortened duration of infection prior to treatment may be
beneficial to the CNS.
Emerging Issues Relating to the CNS in the Setting
of ART
While classical HIV associated dementia (HAD) and progres-
sive milder forms of disease may be presumed to be secondary
to unchecked viral replication and inflammation within the
CNS, HAND which persists or develops on ART is less well
understood. The etiology of incident neurocognitive dysfunc-
tion in ART-suppressed patients is likely multifactorial, but
may include poor access of ART to cells and tissues harboring
HIVinfection within the CNS, smoldering HIVinfectionwhich
‘escapes’ treatment and may be facilitated by immune activa-
tion, and potential antiretroviral toxicity in the nervous system.
Antiretroviral Treatment Strategies for CNS Infection
Due to barriers separating the peripheral circulation and the
brain and CSF compartments, levels of antiretroviral drugs are
reduced in CNS tissues, leading to speculation that systemical-
ly effective ART might fail to control CNS HIV infection. For
the most part, ARTappears to exert salutary effects in suppres-
sion of CSF HIV RNA and inflammation even when it fails to
achieve peripheral viral control [66–68]. Similarly, the dramat-
ic effect of ART in reduction of incidence of HAD supports the
overall success of ART within the CNS compartment [69].
However, more subtle forms of HANDmay persist in part due
to failure of typical ART regimens to completely halt HIV
replication in the brain due to reduced CNS drug exposure.
CSF HIV RNA is generally lower than that in plasma, and
typically decays in parallel to plasma viral load in response to
ART. However, in some cases, CSF decay is delayed in re-
sponse to ART [66], which may be accounted for by poor CNS
penetration, delayed attenuation of replication within long
lived cells such as tissue macrophages, or locally compartmen-
talized HIV variants with distinct resistance profiles.
In recognition of the fact that due to steric or molecular
properties, certain antiretrovirals have decreased potential ac-
cess to the CNS, Letendre and colleagues developed a CNS
penetration-effectiveness (CPE) score to quantitate the putative
CNS effects of each drug, taking into account to varied degrees
the relative concentrations of each drug in CNS tissues, its
ability to reduce CSF load, or affect dementia. Within each
class of antiretrovirals, a CPE value is assigned to each drug,
with higher values associated with presumed higher CNS ef-
fectiveness, and a total CPE score for a regimen calculated by
adding the individual drug scores together [70, 71]. While
higher CPE regimens have been shown to better suppress
CSF HIV RNA levels [71, 72], studies examining the relation
of CPEwith neurologic and cognitive performance have shown
conflicting results. Although in a few longitudinal studies,
subjects with HAND showed better improvement with initia-
tion of higher CPE regimens, results of cross sectional studies
have shown variable results, possibly in part due to initial
selection of high-CPE regimens for more medically or neuro-
logically ill patients [73–77]. Since macrophage and microglial
cells are the primary cells within the CNS productively infected
by HIV, recent investigation has focused on the role of antire-
troviral penetration into monocytes, cells which may serve as
circulating precursors to these cellular reservoirs within the CNS
andwhich have been found by some investigators to be linked to
presence of HAND [78, 79]. Putative ability of individual
antiretrovirals to affect HIV replication within monocyte-
lineage cells has been quantitated as a monocyte efficacy (ME)
score, and one study employing summed ME scores from drug
regimens found this to be a closer predictor of neuropsycholog-
ical performance than CPE [80]. Ideally, randomized clinical
trials of higher as compared to lower CPE and ME regimens
would provide the best data to indicate whether such indices
should be taken into account in treatment of HIV infected in-
dividuals and specifically thosemeeting criteria for HAND. Such
studies are complex and have thus far proved challenging to
implement but current studies are in progress or in development
which should yield new insight into these issues.
Progressive CNS Disease in Well-Treated Patients
For the vast majority of HIV-infected persons, systemically
suppressive ART has resulted in apparent protection of the
CNS from severe progressive neurologic disease, likely through
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a combination of reduced HIV replication within the CNS itself,
reduced systemic as well as CNS immunoactivation, and re-
duced trafficking of immune cells as well as virally-infected
cells to the nervous system. However, recent reports have drawn
attention to the fact that in some rare cases, substantial HIV
infection, inflammation, and clinical disease can evolve and
manifest within the CNS in the setting of HIV treatment. In
the most dramatic examples, patient can have relative immune
preservation or reconstitution and undetectable plasma viral
loads for prolonged periods, but still experience emergent
CNS disorders. When explored carefully, the common features
of patients with these conditions include stable ART therapy,
well-controlled plasma viremia either to consistently unde-
tectable levels or with low-level ‘blips,’ and new and progres-
sive clinical signs and symptoms including new encephalopathy
manifesting as dementia or aphasia, often accompanied by
tremor, ataxia, severe headache, or sensory changes [81••,
82–86]. Upon CSF HIV RNA quantitation, these patients have
findings of CSF HIV RNA levels one log10 greater than plasma
levels or >50 copies/ml where plasma levels are <50 copies/ml.
CNS inflammation manifesting as CSF pleocytosis or in-
creased CSF protein or albumin ratio is also typically associat-
ed, features not present in typical patients on ART. While some
of these reports have included patients with very low CD4
counts or on monotherapy or salvage therapy, others have
described symptomatic CSF escape in persons with
reconstituted immune systems on standard regimens. Because
of the progressive neurological dysfunction noted in the context
of CSF to plasma ‘discordance’ with a pattern different from
that in usual untreated or treated HIV, this syndrome has been
referred to as ‘symptomatic CSF escape.’ These syndromes
with manifest clinical neurologic disease are distinct from
‘asymptomatic CSF escape’ which is detected in a proportion
of HIV-infected individuals undergoing lumbar puncture with-
out symptoms and which has unclear clinical significance [62].
Though the lack of suppression of CSF HIV RNA is a
hallmark of the syndrome, the pathogenesis most likely involves
not only the CSF and meninges, but the brain parenchyma itself,
based on the clinical manifestations of the disorder, neuroimag-
ing which has been reported in several cases to demonstrate
patterns suggestive of cerebral inflammation, and brain patholo-
gy which indicates CD8 T lymphocyte infiltration and wide-
spread inflammation. Indeed, these syndromes are likely on a
continuum with newly described cases of ‘CD8 T cell encepha-
litis’ in which patients with incident and progressive dementia or
clinical encephalitis have been noted to have dramatic infiltration
of CD8 T lymphocytes on biopsy with imaging and CSF evi-
dence of inflammation as well as low-level detectable CSF HIV
[87•, 88]. Though these syndromes are primarily described as
encephalitis from a pathological standpoint, the clinical spectrum
of these conditions likely overlaps with those described primarily
based on CSF analysis as CSF escape cases (see Table 1). Based
on the high CD4 T cell counts of subjects manifesting
encephalitis as well as the fact that the dramatic inflammatory
changes detected pathologically are not accompanied by high
levels of HIV or other antigens, these disorders have been
considered a variant of immune reconstitution inflammatory
syndrome (IRIS) and thus treated in some cases with immu-
nosuppressants. Initiation of ART has been previously identi-
fied to be associated with emergence of leukoencephalopathy
and inflammation suggestive of an IRIS syndrome related
directly to HIV in the brain [89]. In these recent reports of
CD8 encephalitis as well as CSF escape, though inflammation
similarly appears central to the pathology, many cases seem to
arise in the context of stable therapy, suggesting a complex,
perhaps chronic form of IRIS.
Both symptomatic CSF escape and CD8 encephalitis are
likely related to ongoing CNS infection in the CNS compartment
in the context of a substrate of CNS inflammation, usually in the
context of a relatively reconstituted immune system. In many
described cases, genotyping of CSF yields a distinct resistance
pattern in the CNS compartment from that present in plasma, or
evidence of resistance to drugs which successfully suppress
plasma virus. This suggests that one contributor to persistent
HIV production in these disorders may be compartmentalization
of HIV strains within the CNS, perhaps facilitated by poor CNS
exposure of ARTor by prior inconsistent medication adherence.
Additionally, the presence of elevated CNS inflammation in
symptomatic CSF escape and CD8 encephalitis may directly
lead to enhanced production of HIV locally within CNS tissues,
as inflammatory signals lead to increased trafficking of infected
cells, as well as target cells of infection, to the CNS. Many
patients with these disorders have been reported to have clinical
improvement when ART regimens are tailored both to address
resistance genotypes detected in the CSF as well as to improve
presumed blood brain barrier penetration. For this reason, knowl-
edge of these syndromes is critical to the HIV provider and
patient, since substantial clinical improvement or even complete
resolution of symptoms may result from proper diagnosis and
treatment intervention. Additionally, recognition that such con-
ditions can exist provides proof for the concept that a biologically
meaningful reservoir for HIV infection may exist in the CNS
even in the setting of treatment. In one report, CSF escape was
accompanied by recrudescence of low-level plasma viremia,
which was hypothesized to possibly have resulted from
‘reseeding’ of the successfully treated periphery from the CNS
compartment [84]. A number of independent studies have sug-
gested that inflammation and brain injurymay persist in the CNS
in individuals on ART [58, 60, 90]. Overt clinical syndromes
may be the most dramatic examples of a chronic low level
activity within the CNS despite standard ART.
Potential Neurotoxicity of ART
A substantial controversy in the field of neuroAIDS is whether
antiretroviral therapy may be directly toxic to the nervous
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system and itself contribute to HAND. Though numerous
studies and epidemiological observations have demonstrated
the major beneficial effects of effective ART for the CNS, one
study demonstrated improvement in neuropsychological test-
ing performance in a cohort of 167 HIV infected persons
interrupting therapy [91]. Though some improvement may
be observed in individual performance on repeated testing,
the study investigators felt that the improvement observed in
this case was more than would be expected from a practice
effect. Numerous medications in current use have been pos-
tulated to have neurotoxic potential in the CNS. However, the
mechanisms of these effects are unknown, and the limited
studies supporting them are based on in vitromodels that have
unclear clinico-pathologic significance [92, 93].
Individual agents have potential or observed adverse effects
on the CNS. Themost dramatic example of these is the NNRTI
efavirenz, which has a broad array of cognitive and behavioral
effects including insomnia and vivid dreaming, daytime en-
cephalopathy, fatigue, hallucinations, irritability, increased
anxiety and suicidality. Though most of these effects are at
their peak in the first weeks after initiating therapy, many
persist long term and are a central reason for discontinuing or
switching efavirenz-containing regimens [94]. Not only do
patients experience symptoms of disturbed sleep, cognition
and mood, but cognitive impairment may associate with use
of efavirenz. In a recent study of 146 asymptomatic subjects
assessed in routine follow-up visits to an outpatient clinic,
treatment with an efavirenz-containing regimen was indepen-
dently associated with impairment on neuropsychological test-
ing and poor performance on specific tests [95]. Since these
subjects did not have symptoms of impairment, selection bias
for simpler regimens in patients with existing deficits is un-
likely to have confounded this finding. Similarly, in subjects
interrupting ART, those on efavirenz containing regimens had
greater improvement in neuropsychological performance than
those on regimens without efavirenz [91]. A broad antiretrovi-
ral neurotoxicology study identified efavirenz as one among
several antiretrovirals which damaged neurons when directly
applied in vitro [93]. Recently, investigators more specifically
identified damage to neuronal dendrites by metabolites of
efavirenz at concentrations readily detected in CSF of patients
receiving efavirenz containing regimens [92]. However, a
long-term study of subjects followed for 3 years on efavirenz
containing regimens showed stability of neuropsychological
testing performance in subjects with normal testing at baseline,
suggesting if tolerated, efavirenz does not appear to lead to
accumulated neurotoxicity which is clinically detectable [94].
Importantly, the ease of consistently adhering to efavirenz-
containing regimens in terms of convenience of dosing must
be weighed against potential neurotoxicity in terms of cost-
benefit to the CNS. Overall, the benefit conferred by ART in
protecting the CNS likely outweighs any chronic neurotoxic
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may be a rationale for switching drugs. Further prospective,
longitudinal studies are warranted to assess the potential dele-
terious effects of various antiretroviral regimens on the CNS.
Conclusion
Despite the widespread use of ART and its proven effective-
ness in preventing classical HIV-associated dementia, a sub-
stantial proportion of HIV infected individuals meet criteria
for HAND [2••, 7, 8]. Addressing this persistence of neuro-
logic and cognitive symptoms in HIV infected persons is a
major challenge to optimizing quality of life in persons living
with HIV. One possible explanation is that a CNS HIV reser-
voir for infection and inflammation is established in the early
stages of infection, before HIV is typically diagnosed, and this
substrate for HIV-related brain injury leads to irreversible
damage within the CNS before ART is initiated. Another
potential explanation is that in the setting of apparently sys-
temically suppressive ART, processes of infection, inflamma-
tion, and brain injury may be attenuated but remain active,
allowing for progressive impairment on treatment. Finally,
other sequelae of treated HIV infection may contribute to
cognitive impairment, even if classical HIV encephalitis is
eliminated with ART. Future efforts should focus on earlier
diagnosis and treatment of HIVas well as on identification of
optimal antiretroviral and adjunctive therapies to reduce resid-
ual infection and neurotoxicity within the CNS.
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